Bird & Bird advises HSS on SciRhom’s EUR 63 million Series A financing round
International law firm Bird & Bird has advised New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special Surgery (HSS) on EUR 63 million Series A financing round of SciRhom GmbH.
HSS is the world’s leading academic medical centre specialising in Rheumatology and musculoskeletal health and one of the co-founders of SciRhom GmbH.
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. In addition, the new funds will accelerate and broaden the impact of SciRhom’s innovative therapeutic strategy in autoimmune disorders.
SciRhom is a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies. Its mission is to provide a new treatment paradigm for autoimmune diseases and potentially other indications by selectively addressing TACE/ADAM17, a master switch for various autoimmune disease-relevant signalling pathways, via iRhom2.
HSS was advised by the following Bird & Bird lawyers: Counsel Michael Gaßner (lead) and partner Stefan Münch (both Corporate, Munich).